过去二十年间克罗恩病长期结局的改善及其与医疗管理变化的关系:基于人群的IBDSL队列研究结果
该研究纳入1162例克罗恩病患者,按1991-1998年、1999-2005年、2006-2011年三个年代分组并随访至2014年。5年免疫调节剂暴露率从30.6%升至70.8%,生物制剂暴露率从3.1%升至41.2%,住院率从65.9%降至44.2%,手术率从42.9%降至17.4%(均P<0.01),但复杂表型进展率无变化。倾向性评分匹配显示,免疫调节剂或生物制剂使用与住院、手术或表型进展风险无显著相关(均P>0.05)。
要点
- 5年免疫调节剂暴露率从30.6%升至70.8%,生物制剂从3.1%升至41.2%。
- 5年住院率从65.9%降至44.2%,手术率从42.9%降至17.4%(均P<0.01)。
- 复杂表型进展率未随时间变化(21.2% vs 21.3%,P=0.93)。
核心结论
- 1991至2014年间,克罗恩病住院率和手术率下降,但进展为复杂疾病仍常见。
- 这些改善与免疫调节剂和生物制剂的使用无显著相关。
研究设计与样本
- 基于荷兰IBDSL队列的基于人群的队列研究,共纳入1162例克罗恩病患者。
- 分为三个年代:1991-1998年(n=316)、1999-2005年(n=387)、2006-2011年(n=459),随访至2014年。
- 采用Kaplan-Meier生存分析估计药物暴露率及住院、手术和表型进展率,多变量Cox回归模型比较年代间差异。
- 采用倾向性评分匹配评估药物使用与长期结局的关系。
主要发现
- 5年免疫调节剂暴露率从1991-1998年代的30.6%升至2006-2011年代的70.8%。
- 5年生物制剂暴露率从1991-1998年代的3.1%升至2006-2011年代的41.2%。
- 5年住院率从1991-1998年代的65.9%降至2006-2011年代的44.2%,手术率从42.9%降至17.4%(均P<0.01)。
- 进展为复杂表型的比例无变化(1991-1998年代21.2% vs 2006-2011年代21.3%,P=0.93)。
- 免疫调节剂使用者与倾向性评分匹配的非使用者相比,住院、手术或表型进展风险相似(所有分析P>0.05);生物制剂使用者结果相似(所有分析P>0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Medical treatment options and strategies for Crohn's disease (CD) have changed over the past decades. To assess its impact, we studied the evolution of the long-term disease outcome in the Dutch Inflammatory Bowel Disease South Limburg (IBDSL) cohort. METHODS: In total, 1,162 CD patients were included. Three eras were distinguished: 1991-1998 (n=316), 1999-2005 (n=387), and 2006-2011 (n=459), and patients were followed until 2014. Medication exposure and the rates of hospitalization, surgery, and phenotype progression were estimated using Kaplan-Meier survival analyses and compared between eras by multivariable Cox regression models. Second, propensity score matching was used to assess the relation between medication use and the long-term outcome. RESULTS: Over time, the immunomodulator exposure rate increased from 30.6% in the era 1991-1998 to 70.8% in the era 2006-2011 at 5 years. Similar, biological exposure increased from 3.1% (era 1991-1998) to 41.2% (era 2006-2011). In parallel, the hospitalization rate attenuated from 65.9% to 44.2% and the surgery rate from 42.9% to 17.4% at 5 years, respectively (both P<0.01). Progression to a complicated phenotype has not changed over time (21.2% in the era 1991-1998 vs. 21.3% in the era 2006-2011, P=0.93). Immunomodulator users had a similar risk of hospitalization, surgery, or phenotype progression as propensity score-matched nonusers (P>0.05 for all analyses). Similar results were found for biological users (P>0.05 for all analyses). CONCLUSIONS: Between 1991 and 2014, the hospitalization and surgery rates decreased, whereas progression to complicated disease is still common in CD. These improvements were not significantly related to the use of immunomodulators and biologicals.
引用
- Jeuring SF, van den Heuvel TR, Liu LY, et al. Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. Am J Gastroenterol. 2016. PMID: 27922024. doi:10.1038/ajg.2016.524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。